NBL and Tasso, Inc. to Establish Joint Venture in Japan
TOKYO & KAGOSHIMA, Japan & SEATTLE – Tokyo & Kagoshima, Japan (March 28, 2025 JST) / Seattle, Washington, USA (March 27, 2025 PT): Shin Nippon Biomedical Laboratories, Ltd. (TSE Prime: 2395, Representative Chairman, President & CEO: Ryoichi Nagata, M.D., Ph.D.; hereinafter ‘SNBL’) and Tasso, Inc., the Seattle-based leading provider of patient-centric, clinical grade blood collection solutions (Co-founder & CEO: Ben Casavant, Ph.D.; hereinafter ‘Tasso’) hereby announce that they have agreed to establish a new joint venture company (hereinafter ‘JV’) for exclusive distribution of Tasso’s proprietary on-demand blood collection device in Japan.
